Taxonomy / Categories

Zanubrutinib

Molecule

Zanubrutinib

Congress Molecule

Zanubrutinib

Presentation Category

Updated results from the phase 1 study of sonrotoclax (BGB-11417), a novel BCL2 inhibitor, in combination with zanubrutinib for relapsed/refractory CLL/SLL show deep and durable responses

Congress Resource

A Network Meta-Analysis (NMA) of Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax in Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL)

Congress Resource

Combination of Zanubrutinib + Venetoclax for Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results in SEQUOIA Arm D

Congress Resource

Comparative Efficacy of Zanubrutinib Versus Fixed-Duration Acalabrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)

Congress Resource

Estimating the Cardiac Deaths Associated With Treating Chronic Lymphocytic Leukemia With Ibrutinib Versus Zanubrutinib in the United States

Congress Resource

Safety and Efficacy of Zanubrutinib in a Subgroup of Older Patients (≥75 Years) With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma From the SEQUOIA Study

Congress Resource

SEQUOIA 5-Year Follow-Up in Arm C: Frontline Zanubrutinib Monotherapy in Patients With del(17p) and Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Congress Resource

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

Publication

Zanubrutinib for the treatment of B-cell malignancies

Publication

A two-part, single-arm, multicentre, phase I study of zanubrutinib, a selective Bruton tyrosine kinase inhibitor, in Chinese patients with relapsed/refractory B-cell malignancies

Publication